| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/07/2005 | WO2005011586A3 Treatment and preventi0n of cardiovascular events |
| 07/07/2005 | WO2005007086A3 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 07/07/2005 | WO2005007082A8 Treatment of chronic bacterial infection |
| 07/07/2005 | WO2004091500A3 Delivery of immune response modifier compounds |
| 07/07/2005 | WO2004060369A8 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes |
| 07/07/2005 | WO2003089583A3 Tissue specific genes and gene clusters |
| 07/07/2005 | WO2003053360A3 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 07/07/2005 | US20050149118 High strength suture with absorbable core and suture anchor combination |
| 07/07/2005 | US20050148673 Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
| 07/07/2005 | US20050148661 calcium is in gluconate, chloride, bromogalactogluconate, gluconolactate or carbonate form, and the magnesium is in sulfate or pidolate form |
| 07/07/2005 | US20050148648 Cystic fibrosis transmembrane conductance regulator; ABC transporter mediated diseases like cystic fibrosis; 5-methoxy-N-((1-(3,4-dimethoxyphenyl)-cyclohexyl)methyl)benzofuran-2-carboxamide; or sulfonamide analogs; chloride or bicarbonate channel modulators |
| 07/07/2005 | US20050148644 Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative |
| 07/07/2005 | US20050148637 Neurotrophic low molecular weight ketones and tioester compounds for treatment of nervous system disorders and neurodegenerative conditions |
| 07/07/2005 | US20050148626 Novel thromodulin expression promoters |
| 07/07/2005 | US20050148607 Administering to show overactivation or expression from diagnosis of diseases, immunoassay, anticancer agents or skin disorders |
| 07/07/2005 | US20050148584 N-(3-(2-(4-morpholino)ethyloxy)phenyl)-N-{(cis3-(benzylamino)cyclohexyl)methyl}-N'-phenylurea; useful for the treatment of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome |
| 07/07/2005 | US20050148570 Antimicrobial hydroxy-substituted fluorene or (cyclo)alkylidenediphenol derivatives e.g. 2,2-Bis(4-hydroxy-3-methylphenyl)heptane or penem or cephalosporin derivatives thereof; antiseptics |
| 07/07/2005 | US20050148562 Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| 07/07/2005 | US20050148559 Fewer side effects; usable for longer period of time; lower recurrence rates after discontinuation; combination of progestogen and androgen components; kits |
| 07/07/2005 | US20050148557 Use of Vitamin Ds to treat kidney disease |
| 07/07/2005 | US20050148555 Synergistic use of p38 MAP kinase inhibitor and second active ingredient; inhibiting cytokine production; chronic obstructive pulmonary disease (COPD) |
| 07/07/2005 | US20050148548 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors |
| 07/07/2005 | US20050148545 Better tasting dietary supplements; combined with such as citric acid |
| 07/07/2005 | US20050148537 Immunostimulatory nucleic acid molecules |
| 07/07/2005 | US20050148527 Catalytic nucleic acids; ribozymes; translation inhibition; gene expression inhibition; for treating cardiovascular disease; for neovascularization induction in heart tissue |
| 07/07/2005 | US20050148525 Nucleic acid markers |
| 07/07/2005 | US20050148524 Treating multiple myeloma via administering thalidomide and topoisomerase inhibitor such as irinotecan; side effect reduction |
| 07/07/2005 | US20050148521 Coadministration with non-steroidal antiinflammatory agent allows for lower dosage of cyclophosphamide; side effect reduction; kits |
| 07/07/2005 | US20050148519 Comprises non-steroidal anti-inflammatory (such as flunixin, carprofen, ibuprofen, diclofenac, and naproxen) and antibiotic (such as azithromycin, roxythromycin, tilmicosin, oxytetracycline and doxycycline) |
| 07/07/2005 | US20050148502 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43 |
| 07/07/2005 | US20050148501 Methods of inducing ovulation using a non-polypeptide camp level modulator |
| 07/07/2005 | US20050148499 immunological oral tolerance-inducing amount of an active ingredient beta 2-glycoprotein-1or derivatives |
| 07/07/2005 | US20050148496 Methotrexate resistant, a TNF- alpha antagonist, an interleukin-1 receptor antagonist and a steroid; drug screening; |
| 07/07/2005 | US20050148062 Transgenic microorganisms comprising apoptosis associated genes for use as tools in identifying modulators for prevention and treatment of cell proliferative disorders |
| 07/07/2005 | US20050148034 Using reduced microvessel outgrowth of pluripotent stem cells as diagnostic indicator angoigenseis inhibition; antitumor agents |
| 07/07/2005 | US20050148014 Regulation of human P2Y1-like G protein-coupled receptor |
| 07/07/2005 | US20050148013 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 07/07/2005 | US20050147969 Genes associated with mast cell activation |
| 07/07/2005 | US20050147723 Phytochemical preservation, drying and grinding; maintaining high phenolic and flavonoid content; antioxidative and antiproliferative properties |
| 07/07/2005 | US20050147694 Administering a mono-, di- , tri-, or, preferably, tetrathiomolybdate that binds/complexes endogenous copper to form an irreversible tripartite agent-copper-protein complex; chelation; side effect reduction; pulmonary, cystic, pancreatic, myocardial, gastrointestinal fibrosis, acute respiratory distress |
| 07/07/2005 | US20050147689 Method for inhibiting the growth of gastrointestinal tract tumors |
| 07/07/2005 | US20050147662 Compounds and compositions for delivering active agents |
| 07/07/2005 | US20050147649 Method and dietary composition for improving fat digestibility |
| 07/07/2005 | US20050147631 comprising mixtures of an ornithine decarboxylase inhibitor, angiogenesis inhibitors, antiinflammatory agents and cosmetically acceptable vehicles |
| 07/07/2005 | US20050147629 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 07/07/2005 | US20050147607 administering interleukin antagonists, for prophylaxis of respiratory system disorders |
| 07/07/2005 | US20050147595 Such as calcium crosslinked alginate containing pancreatic islets; free of adventitious excipients; do not dissolve in media or intraperitoneal cavity; durable, nontoxic transplant materials; diabetes |
| 07/07/2005 | US20050147591 Methods and compositions for viral enhancement of cell killing |
| 07/07/2005 | US20050147574 Inhibitors of proteasomal activity for stimulating hair growth |
| 07/07/2005 | US20050147567 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 07/07/2005 | US20050147564 Inhalable formulation of a solution containing a tiotropium salt |
| 07/07/2005 | DE202005006624U1 Verpackungseinheit für Rohstoffe für ein Dialysekonzentrat Package for raw materials for a dialysis concentrate |
| 07/07/2005 | DE10357970A1 Lösungsmittel für biogene pharmazeutische Wirkstoffe Solvent for biogenic active pharmaceutical ingredients |
| 07/07/2005 | DE10356815A1 Use of an angiotensin II receptor antagonist for treating type 2 diabetes or prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure |
| 07/07/2005 | DE10356567A1 Radiosensibilisatoren und Herstellungsverfahren Radiosensitizers and methods of manufacture |
| 07/07/2005 | DE10355400A1 Multikomponenten Mineralstoffpräparate und Verfahren zur Herstellung von Multikomponenten-Mineralstoffpräparaten Multi-component mineral preparations and methods for the production of multi-component mineral supplements |
| 07/07/2005 | DE10346950A1 Four-component herbal composition in form of capsules, useful for long-term, pre- or post-operative treatment of malignant tumors |
| 07/07/2005 | CA2792483A1 Hiv protease inhibiting sulfonamides |
| 07/07/2005 | CA2551546A1 Preventive/remedy for cancer |
| 07/07/2005 | CA2551543A1 Method of suppressing cancer |
| 07/07/2005 | CA2550900A1 Methods for detecting markers associated with endometrial disease or phase |
| 07/07/2005 | CA2550300A1 Polymetaphosphate based formulations for therapy of microcrystalline arthropathies |
| 07/07/2005 | CA2550294A1 Canine probiotic lactobacilli |
| 07/07/2005 | CA2550064A1 Methods of treating acute inflammation in animals with p38 map kinase inhibitors |
| 07/07/2005 | CA2549935A1 Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen |
| 07/07/2005 | CA2549712A1 Identification of a gene expression profile that differentiates ischemic and nonischemic cardiomyopathy |
| 07/07/2005 | CA2549429A1 Fat composition |
| 07/07/2005 | CA2549389A1 Hiv protease inhibiting sulfonamides |
| 07/07/2005 | CA2549116A1 Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
| 07/07/2005 | CA2549114A1 Immunostimulant composition comprising at least one toll-like 7 receptor or toll-like 8 receptor agonist and a toll-like 4 receptor agonist |
| 07/07/2005 | CA2548917A1 Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| 07/07/2005 | CA2548108A1 Use of superoxide dismutase mimetics and reductase glutathione in the form of anticancer drugs |
| 07/07/2005 | CA2546565A1 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and an agent intervening in the prostaglandin metabolism |
| 07/06/2005 | EP1550720A1 Mutated androgen receptor, cancer cells expressing the same, method of constructing the same and use thereof |
| 07/06/2005 | EP1550675A1 Phospholipid derivative |
| 07/06/2005 | EP1550462A1 Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| 07/06/2005 | EP1550460A1 Method for correcting immune responses and medicinal agent |
| 07/06/2005 | EP1550459A1 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 07/06/2005 | EP1550456A2 Use of botulinum toxin in the treatment of burn pain |
| 07/06/2005 | EP1550454A1 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/06/2005 | EP1550452A1 Composition comprising an aqueous extract of red vine leaves and a antthrombotic agent for the treatment of chronic venous insufficiencies |
| 07/06/2005 | EP1550451A1 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiencies |
| 07/06/2005 | EP1550450A1 Composition comprising an aqueous extract of red vine leaves and a blood circulating-improving agent for the treatment of chronic venous insufficiencies |
| 07/06/2005 | EP1550446A1 Use of 1-(5-isoquinolinesulfonyl) homopiperazine for treating and preventing hypopigmentary disorders |
| 07/06/2005 | EP1550443A1 Composition against stress-related diseases |
| 07/06/2005 | EP1550442A1 Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction |
| 07/06/2005 | EP1550441A1 Compositions for a synergic topical therapy of neuromuscular pain |
| 07/06/2005 | EP1549950A1 Methods for identifying glucose uptake modulators |
| 07/06/2005 | EP1549351A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 07/06/2005 | EP1549348A1 Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity |
| 07/06/2005 | EP1549347A1 Modulation of immune function |
| 07/06/2005 | EP1549320A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 07/06/2005 | EP1549313A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 07/06/2005 | EP1549312A1 Sequential therapy comprising a 20(s)-camptothecin and an anthracycline |
| 07/06/2005 | EP1549311A1 Potent inhibitor of hcv serine protease |
| 07/06/2005 | EP1549308A1 An inhibitor of the shh signalling pathway and a testosterone supressing agent for the treatment of cancer |
| 07/06/2005 | EP1549307A2 Agent for medicamentous treatment of acute and chronic pain |
| 07/06/2005 | EP1549302A1 Gastrointestinal compositions comprising gaba derivatives |
| 07/06/2005 | EP1549277A1 Induction and maintenance of tolerance to composite tissue allografts |
| 07/06/2005 | EP1549143A2 Antibacterial pyrazole carboxylic acid hydrazides |